Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa
Recruiting
Observational Study
Hidradenitis Suppurativa (HS)
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 50 (estimated)
- Sponsor
- Peking Union Medical College · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS). The study was conducted from June 1, 2025, to June 1, 2026, and all participants were treated at the Department of Dermatology, Peking Union Medical College Hospital. The study was approved by the Clinical and Research Ethics Co…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* age ≥18 years
* diagnosis of moderate-to-severe HS with Hurley stage II or III
* Disease duration of ≥6 months, presence of at least one draining tunnel or two inflammatory nodules
* inadequate response to prior treatments, such as antibiotics, isotretinoin, or TNF inhibitors
…
Contacts
No contact information available.